Floatz logo

Cerezyme® / Imiglucerase

Gaucher Disease

University Hospital, Clermont-FerrandUNKNOWNPhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Gaucher Disease cohort.

Asset / SponsorPhaseRating
Taliglucerase Alfa
Protalix
Phase 4A
Velaglucerase Alfa
Takeda
Phase 4A
.ALPHA.-D-GLUCOSYL-N-ACYLSPHINGOSINE GLUCOHYDROLASE
Sanofi
Phase 4A
Eliglustat
Peking Union Medical College Hospital
Phase 3BBB
ISOFAGOMINE
Amicus Therapeutics
Phase 2BB

View all 28 →

Same molecule, other indications

Cerezyme® / Imiglucerase is also rated in:

Gaucher disease type IDormant
NR
Indicative · Phase 4
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →